How Sturdy Is PK/PD Bridge Between Epinephrine Injection Products And Nasal Spray?
Executive Summary
FDA enumerates uncertainties in determining whether PK/PD results support a favorable risk-benefit assessment for use of ARS Pharmaceuticals’ epinephrine nasal spray for emergency treatment of allergic reactions, including anaphylaxis.
You may also be interested in...
Viatris Asks FDA Not To Approve Neffy Until Sponsor Conducts More PK/PD Studies
EpiPen maker says available evidence does not answer questions about how an intranasal epinephrine from ARS Pharmaceuticals will perform in a real-world anaphylaxis event. Viatris citizen petition argues issues raised at advisory committee were not resolved.
FDA Panel Takes ‘Leap Of Faith’ In Backing Epinephrine Nasal Spray For Anaphylaxis
In a split vote, advisory committee finds PK/PD data support favorable benefit-risk assessment of ARS Pharmaceuticals’ neffy, but calls for postmarket studies to evaluate its clinical efficacy.
Keeping Track: More Rx-To-OTC Switches On Deck After US FDA’s OTC Narcan Approval; Iovance Looks To Bring Cell Therapy To Melanoma
The latest drug development news and highlights form the Pink Sheet’s US FDA Performance Tracker.